147 related articles for article (PubMed ID: 11098484)
1. UFT: mechanism of drug action.
Köhne CH; Peters GJ
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):13-8. PubMed ID: 11098484
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
3. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
4. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
5. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G
Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer.
Ichikura T; Tomimatsu S; Okusa Y; Yahara T; Uefuji K; Tamakuma S
Cancer Chemother Pharmacol; 1996; 38(5):401-5. PubMed ID: 8765432
[TBL] [Abstract][Full Text] [Related]
7. The oral fluoropyrimidines in cancer chemotherapy.
Lamont EB; Schilsky RL
Clin Cancer Res; 1999 Sep; 5(9):2289-96. PubMed ID: 10499595
[TBL] [Abstract][Full Text] [Related]
8. [5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
Maruyama M; Ebuchi M; Nagahama T; Takashima I; Hasegawa K; Ochiai T; Natui S
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2109-11. PubMed ID: 12484014
[TBL] [Abstract][Full Text] [Related]
9. [Effects of combination chemotherapy with topical application of 5-FU ointment to mice's tongue and UFT].
Tateishi A; Sakaki Y; Kameyama Y; Hara I; Yamada N
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1877-85. PubMed ID: 2118335
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
Milano G; Ferrero JM; François E
Br J Cancer; 2004 Aug; 91(4):613-7. PubMed ID: 15280932
[TBL] [Abstract][Full Text] [Related]
11. Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma.
Hisamitsu K; Tsujitani S; Yamaguchi K; Fukuda K; Konishi I; Kaibara N
Anticancer Res; 2004; 24(4):2495-501. PubMed ID: 15330204
[TBL] [Abstract][Full Text] [Related]
12. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Inoue S; Ohtani H; Tsujimoto M; Hori S; Sawada Y
Drug Metab Pharmacokinet; 2007 Jun; 22(3):162-8. PubMed ID: 17603216
[TBL] [Abstract][Full Text] [Related]
13. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
14. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Papamichael D
Stem Cells; 2000; 18(3):166-75. PubMed ID: 10840069
[TBL] [Abstract][Full Text] [Related]
15. Oral therapy for colorectal cancer: how to choose.
Damjanov N; Meropol NJ
Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
[TBL] [Abstract][Full Text] [Related]
16. [Studies on 5-FU concentration in serum and prostate cancer tissue after oral administration of UFT].
Shinoda I; Takahashi Y; Takeuchi T; Kuriyama M; Ban Y; Kawada Y; Ito Y; Yamamoto N; Maeda S; Tada K
Hinyokika Kiyo; 1991 Jul; 37(7):711-5. PubMed ID: 1927771
[TBL] [Abstract][Full Text] [Related]
17. [A study of urinary tegafur, 5-fluorouracil (5-FU) and uracil concentrations in the cases of gastric carcinoma for the confirmation of drug-taking compliance after UFT oral administration].
Ohsawa S; Kondo Y; Shiroto H; Masuko H; Fukushima T; Kataoka A; Ohmori K; Sawaguchi Y; Baba E; Takahashi T
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2189-93. PubMed ID: 1444485
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
19. [Study on the concentrations of 5-fluorouracil (5-FU), tegafur (ET) and uracil in bile: comparison of UFT or FT].
Tomita T; Tajima T; Ishibashi M; Tagaya N; Aoki H; Itoh S; Kadowaki A; Kogure H; Tajima Y
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3755-62. PubMed ID: 2512859
[TBL] [Abstract][Full Text] [Related]
20. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
